🟢 Chimeric Therapeutics is trading 11.11% up today after stopping CHM-2101 enrolment and dosing

Chimeric Therapeutics is trading 11.11% up at A$0.02 after stopping CHM-2101 enrolment and dosing on August 19, 2026, following dose-limiting toxicity in a second Dose Level 3 patient.

• The company will not progress the therapy in its current autologous CAR-T form and is exploring alternatives.
• The ASX announcement confirms the trial pause and protocol-driven cessation of dosing.
• The move follows a 45.71% drop on August 19; no volume data or separate August 24 announcement was identified.